文献速递消化道肿瘤放疗

吉西他滨同步质子放疗治疗非转移性局部晚期胰腺癌长期生存相关因素:单中心回顾性研究

Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.
PubMed 文献 · Radiat Oncol · 2022-02-10

本研究回顾性分析了2009年2月至2019年12月在兵库离子束医疗中心接受吉西他滨同步质子放疗(GPT)的123例非转移性局部晚期胰腺癌(LAPC)患者,中位总生存期为18.7个月。多因素分析显示,肿瘤位于胰体尾及无胰腺前方侵犯与更长总生存独立相关(P=0.040和P=0.015)。作者认为GPT对胰体尾LAPC及无胰腺前方侵犯的LAPC患者是有前景的治疗选择。

要点

  • GPT治疗非转移性LAPC的中位总生存期为18.7个月,1年和2年总生存率分别为70.4%和35.7%。
  • 胰体尾LAPC和无胰腺前方侵犯的LAPC与更长总生存独立相关(P=0.040和P=0.015)。
  • 胰体尾LAPC较胰头LAPC有更高比例的肿瘤体积接受超过60 Gy等效剂量照射(P<0.001)。

核心结论

  • GPT是胰体尾LAPC及无胰腺前方侵犯的LAPC患者有前景的治疗选择。

研究设计与样本

  • 单中心回顾性研究,纳入2009年2月至2019年12月在兵库离子束医疗中心接受GPT治疗的123例非转移性LAPC患者。

主要发现

  • 接受GPT治疗的全部队列中位总生存期为18.7个月。
  • 1年和2年总生存率分别为70.4%和35.7%,局部无进展生存率分别为78.2%和59.0%,无进展生存率分别为38.6%和20.8%。
  • 多因素分析显示,胰体尾LAPC和无胰腺前方侵犯的LAPC与更长总生存独立相关(P=0.040和P=0.015)。
  • 胰体尾LAPC患者和無胰腺前方侵犯的LAPC患者的中位总生存期分别为24.1个月和28.1个月。
  • 胰体尾LAPC较胰头LAPC有更高比例的肿瘤体积接受超过60 Gy等效剂量照射(P<0.001);有胰腺前方侵犯的LAPC较无胰腺前方侵犯者GPT后6个月内腹膜复发更多(P=0.039)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the factors associated with long-term survival in GPT for non-metastatic LAPC. METHODS: The medical records of 123 patients with LAPC treated with GPT between February 2009 and December 2019 at Hyogo Ion Beam Medical Center were retrospectively reviewed to assess the factors associated with long-term survival outcomes. RESULTS: The median overall survival of the total cohort treated with GPT was 18.7 months. The 1- and 2-year overall, local progression-free, and progression-free survival rates were 70.4% and 35.7%, 78.2% and 59.0%, and 38.6% and 20.8%, respectively. Multivariate analysis revealed that LAPCs at the pancreatic body-tail and those without anterior peripancreatic invasion were independently associated with longer overall survival (P = 0.040 and P = 0.015, respectively). The median overall survival of patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion were 24.1 and 28.1 months, respectively. LAPCs at the pancreatic body-tail had a higher volume ratio irradiated over 60 Gy equivalents at gross tumor volume than those at the pancreatic head (P < 0.001). LAPCs with anterior peripancreatic invasion had more peritoneal recurrence within 6 months after GTP than those without anterior peripancreatic invasion (P = 0.039). CONCLUSIONS: GPT is a promising treatment option for patients with LAPC at the pancreatic body-tail and those with LAPC without anterior peripancreatic invasion.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ogura Y, Terashima K, Nanno Y, et al. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study. Radiat Oncol. 2022. PMID: 35144647. doi:10.1186/s13014-022-02001-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。